KPTI

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 1, 2024
KPTI, Employment, RSU, Pharmaceutical industry

NEWTON, Mass., April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees.

Key Points: 
  • NEWTON, Mass., April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees.
  • These RSU awards were granted as of March 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date.
  • The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Retrieved on: 
Wednesday, March 6, 2024
KPTI, Barclays, Conference

NEWTON, Mass., March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m.

Key Points: 
  • NEWTON, Mass., March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m.
  • ET in Miami Beach, FL.
  • A live webcast of the fireside chat at the Barclays conference can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations , and will be available for replay following the event.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 1, 2024
KPTI, Employment, RSU, Pharmaceutical industry

NEWTON, Mass., March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,250 restricted stock units (RSUs) to two newly-hired employees.

Key Points: 
  • NEWTON, Mass., March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,250 restricted stock units (RSUs) to two newly-hired employees.
  • These RSU awards were granted as of February 29, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date.
  • The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Retrieved on: 
Thursday, February 22, 2024
KPTI, Therapy, Conference

NEWTON, Mass., Feb. 22, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 29, 2024, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., Feb. 22, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024.
  • Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m.
  • ET on Thursday, February 29, 2024, to discuss the financial results and other company updates.
  • An archived webcast will be available on the Company's website approximately two hours after the event.

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
Conference, KPTI

NEWTON, Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.

Key Points: 
  • NEWTON, Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.
  • A live webcast of the presentation, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations , and will be available for replay for 30 days following the event.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 2, 2024
Employment, KPTI, RSU, Pharmaceutical industry

NEWTON, Mass., Jan. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 42,000 restricted stock units (RSUs) to one newly-hired employee.

Key Points: 
  • NEWTON, Mass., Jan. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 42,000 restricted stock units (RSUs) to one newly-hired employee.
  • This RSU award was granted as of December 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date.
  • The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

Karyopharm to Participate at Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 8, 2023
KPTI, Pharmaceutical industry, Online shopping

NEWTON, Mass., Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:

Key Points: 
  • NEWTON, Mass., Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:
    A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations , and will be available for replay for 90 days following each presentation.

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023

Retrieved on: 
Thursday, October 26, 2023
KPTI, Conference, Therapy, Pharmaceutical industry

NEWTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2023 financial results on Thursday, November 2, 2023. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, November 2, 2023, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2023 financial results on Thursday, November 2, 2023.
  • Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m.
  • ET on Thursday, November 2, 2023, to discuss the financial results and other company updates.
  • An archived webcast will be available on the Company's website approximately two hours after the event.

Karyopharm to Participate at Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 5, 2023
KPTI, Pharmaceutical industry, Online shopping

NEWTON, Mass., Sept. 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

Key Points: 
  • NEWTON, Mass., Sept. 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
    A live webcast of the presentation and fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations , and will be available for replay for 90 days following each presentation.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 1, 2023
KPTI, Employment, RSU, Pharmaceutical industry

NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 58,850 restricted stock units (RSUs) to six newly-hired employees.

Key Points: 
  • NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 58,850 restricted stock units (RSUs) to six newly-hired employees.
  • These RSU awards were granted as of August 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date.
  • The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.